EXCLUSIVE: Small MedTech Firm NeurAxis Targets $2B Market With Post-Concussion Therapy In Kids
Portfolio Pulse from Vandana Singh
NeurAxis Inc (NYSE:NRXS) is conducting a randomized, double-blind, placebo-controlled trial to evaluate the efficacy of IB-Stim in children with post-concussion symptoms. The company's President and CEO, Brian Carrico, stated that positive data and FDA clearance could lead to a groundbreaking therapeutic option for post-concussion syndrome. The trial is currently enrolling up to 100 patients and is being conducted at Children's Hospital of Orange County, CA.
August 29, 2023 | 12:54 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
NeurAxis Inc is conducting a trial for a new therapy for post-concussion symptoms in children. Positive results could significantly impact the company's position in the $2B market.
The news is directly related to NeurAxis Inc and its ongoing clinical trial. If the trial results are positive and the FDA approves the therapy, it could significantly boost the company's market position and potentially its stock price. However, the outcome of the trial is uncertain, hence the confidence score is not at the maximum.
CONFIDENCE 70
IMPORTANCE 80
RELEVANCE 100